별첨2

배제문헌

문헌배제사유

1. 인간 대상 연구가 아닌 경우(동물연구 또는 전임상연구)
2. 원저가 아닌 연구(종설, letter, comment 등)
3. 회색문헌으로 동료심사(peer-review)된 학술지에 게재되지 않은 문헌(초록만 발표된 연구, 학위논문, 기관보고서 등)
4. 한국어 또는 영어로 출판되지 않은 문헌
5. 만성 간 질환자를 대상으로 하지 않은 문헌
6. M2BPGi[정밀면역검사]를 수행하지 않은 문헌
7. 적절한 의료결과를 하나 이상 보고하지 않은 문헌(예후예측, 적절하지 않은 참고표준검사 등)
8. 중복 출판된 문헌(대상자가 중복되고, 보고된 결과지표도 동일한 연구)
9. 원문 확보 불가

연번	서지정보	배제사유
1	허미나, 박미경, 문희원, 최원혁, 이채훈. Comparison of Non-Invasive Clinical Algorithms for Liver Fibrosis in Patients With Chronic Hepatitis B to Reduce the Need for Liver Biopsy: Application of Enhanced Liver Fibrosis and Mac-2 Binding Protein Glycosylation Isomer. Annals of Laboratory Medicine. 2022;42(2):249-57.	7
2	Tajiri H, Suzuki M, Bessho K, Ito Y, Murakami J, Hatori R, et al. The role of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in the assessment of fibrosis in children with chronic hepatitis C. Scientific reports. 2022;12(1):11205.	7
3	Cheng YM, Wang CC. Comparison of Mac-2 binding protein glycosylation isomer (M2BPGi) with AST to platelet ratio index (APRI), fibrosis 4 Score (FIB-4), and nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) for NAFLD patients. Advances in Digestive Medicine. 2022.	7
4	Ishikawa T, Kodama E, Kobayashi T, Azumi M, Nozawa Y, Iwanaga A, et al. Clinical efficacy of Mac-2-binding protein glycosylation isomer as a biomarker for albumin-bilirubin grade and the Controlling Nutritional Status score in chronic liver disease: investigation of cut-off values by the type of chronic liver disease. Annals of palliative medicine. 2022.	7
5	Mak LY, Wong DKH, Cheung KS, Hui RWH, Liu F, Fung J, et al. Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection. Digestive Diseases and Sciences. 2022.	7

6	Toyoda H, Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, et al. Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection. European radiology. 2022;32(7):5016-23.	7
7	서광일, 황현용, 윤병철, 문형환, 최영일, 신동훈, et al. A prospective study of the correlation between hepatic fibrosis and noninvasively measured fibrosis markers including serum M2BPGi and acoustic radiation force impulse elastography. Kosin Medical Journal. 2022;37(2):146-53.	5
8	Ando W, Kaneko F, Shimamoto S, Igarashi K, Otori K, Yokomori H. Long-term prediction of hepatocellular carcinoma using serum autotaxin levels after antiviral therapy for hepatitis C. Annals of hepatology. 2022;27(2):100660.	6
9	Arinaga-Hino T, Ide T, Akiba J, Suzuki H, Kuwahara R, Amano K, et al. Growth differentiation factor 15 as a novel diagnostic and therapeutic marker for autoimmune hepatitis. Scientific reports. 2022;12(1):8759.	7
10	Choi R, Chun G, Go U, Lee SG, Lee EH. Biological variation and reference change values of serum Mac-2-binding protein glycosylation isomer (M2BPGi). Journal of clinical laboratory analysis. 2022;36(4):e24319.	5
11	Choi R, Kim CW, Lee SG, Lee EH. Intraindividual Changes in Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Performed in Korean Subjects. Clinical laboratory. 2022;68(2).	5
12	Hagiwara K, Harimoto N, Yamanaka T, Ishii N, Yokobori T, Tsukagoshi M, et al. A new liver regeneration molecular mechanism involving hepatic stellate cells, Kupffer cells, and glucose-regulated protein 78 as a new hepatotrophic factor. Journal of hepato-biliary-pancreatic sciences. 2022.	7
13	Harimoto N, Itoh S, Yamanaka T, Hagiwara K, Ishii N, Tsukagoshi M, et al. Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response. Anticancer research. 2022;42(1):245-51.	7
14	Igarashi T, Harimoto N, Muranushi R, Yamanaka T, Hagiwara K, Hoshino K, et al. Does intraoperative and postoperative analgesia cause bile leakage after hepatectomy? Surgery today. 2022;52(4):690-6.	7
15	Kamada Y, Nakahara T, Munekage K, Fujii H, Sawai Y, Doi Y, et al. Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with NAFLD. Hepatology Communications. 2022;6(7):1527-36.	7
16	Kawata K, Atsukawa M, Ohta K, Chida T, Noritake H, Arai T, et al. Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C. Hepatology communications. 2022;6(8):1855-69.	7
17	Kim MJ, Kwon Y, Kim ES, Choe YH. Stratification by non-invasive biomarkers of non-alcoholic fatty liver disease in children. Journal of Pediatric Gastroenterology and Nutrition. 2022;74(2 Supplement 2):784.	3
18	Lin MT, Chiu SYH, Chang KC, Li WF, Yong CC, Liu YW, et al. Significant association between serum Wisteria floribunda agglutinin-positive Mac-2-binding protein and prognosis of hepatocellular carcinoma after surgical treatment. American Journal of Cancer Research. 2022;12(2):601-14.	7
19	Maruyama S, Matono T, Koda M. Prevalence and Characteristics of Hepatic Hemangioma Associated with Coagulopathy and Its Predictive Risk Factors. Journal of clinical medicine. 2022;11(15).	7
20	Nah E, Cho S, Kim S, Kim HS, Cho H. Diagnostic performance of MAC-2 binding protein glycosylated isomer (M2BPGI) in predicting liver fibrosis in health checkups. Clinica Chimica Acta. 2022;530(Supplement 1):S189.	5

21	Suzuki T, Matsuura K, Nagura Y, Ogawa S, Fujiwara K, Nojiri S, et al. Serum angiopoietin-2 levels predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents. Hepatology research : the official journal of the Japan Society of Hepatology. 2022.	7
22	Tamaki N, Kurosaki M, Huang DQ, Loomba R. Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. Hepatology Research. 2022;52(6):497-507.	2
23	Yang Q, Sun C, Sheng Y, Chen W, Deng C. The Biomarkers for Predicting Viral Hepatitis-Associated Hepatocellular Carcinoma. Turkish Journal of Gastroenterology. 2022;33(1):1-7.	7
24	Yugawa K, Maeda T, Nagata S, Sakai A, Edagawa M, Omine T, et al. ASO Visual Abstract: Mac-2 Binding Protein Glycosylation Isomer as a Novel Predictor of Hepatocellular Carcinoma Recurrence in Patients with Hepatitis C Virus Eradication. Annals of surgical oncology. 2022.	3
25	Yugawa K, Maeda T, Nagata S, Sakai A, Edagawa M, Omine T, et al. Mac-2-Binding Protein Glycosylation Isomer as a Novel Predictor of Hepatocellular Carcinoma Recurrence in Patients with Hepatitis C Virus Eradication. Annals of surgical oncology. 2022;29(4):2711-9.	7
26	Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, et al. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PloS one. 2021;16(9):e0257166.	7
27	Cheng YM, Wang CC. Serum mac-2 binding protein glycosylation isomer (M2bpgi) can predict mild or significant liver fibrosis in non-alcoholic fatty liver disease. Hepatitis Monthly. 2021;21(5):e115400.	7
28	Chuaypen N, Chittmittrapap S, Avihingsanon A, Siripongsakun S, Wongpiyabovorn J, Tanpowpong N, et al. Liver fibrosis improvement assessed by magnetic resonance elastography and Mac-2-binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct-acting antivirals. Hepatology research : the official journal of the Japan Society of Hepatology. 2021;51(5):528-37.	7
29	Arai T, Atsukawa M, Tsubota A, Kato K, Abe H, Ono H, et al. Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. Scientific reports. 2021;11(1):15938.	7
30	Dong MP, Thuy LTT, Hai H, Hieu VN, Hoang DV, Uchida-Kobayashi S, et al. Levels of soluble immune checkpoint proteins following antiviral treatment in chronic hepatitis c patients and the roles of scd27 in hepatocellular carcinoma development. Hepatology. 2021;74(SUPPL 1):610A-1A.	7
31	Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Takeda H, et al. Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma. Journal of hepato-biliary-pancreatic sciences. 2021;28(6):498-507.	7
32	Euctr ES. A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis. https://trialsearchwhoint/Trial2aspx?TrialID=EUCTR2021-003901-23-ES. 2021.	7
33	Gantumur D, Harimoto N, Muranushi R, Hoshino K, Batbayar C, Hagiwara K, et al. Hepatic stellate cell as a Mac-2-binding protein-producing cell in patients with liver fibrosis. Hepatology research : the official journal of the Japan Society of Hepatology. 2021;51(10):1058-63.	7
34	Hayashi S, Nagaoka K, Tanaka Y. Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins. International journal of molecular sciences. 2021;22(20).	2

35	Heriyanto R, Tandiono J, Marcella E, Susanto B, Chen S, Jonathan C, et al. Efficacy of MAC-2 binding protein glycosylation isomer as fibrosis presence and severity biomarker in hepatitis: A systematic review. Gut. 2021;70(SUPPL 2):A70.	2
36	Imai K, Takai K, Miwa T, Maeda T, Hanai T, Shirakami Y, et al. Higher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic Livers. Cancers. 2021;13(23).	7
37	Kawaguchi T, Ide T, Amano K, Arinaga-Hino T, Kuwahara R, Sano T, et al. Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication. Molecular and clinical oncology. 2021;15(4):215.	7
38	Keddeas MW, Kaisar HH, Elessawy HAA, Abdel Hamid Elewa MS. Role of serum M2BPGi levels in diagnosing significant liver fibrosis and cirrhosis in patients with chronic hepatitis B. QJM. 2021;114(SUPPL 1).	3
39	Kimura Y, Taura K, Nguyen HN, Uemoto Y, Seo S, Iwaisako K, et al. Usefulness of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) for Evaluating Graft Status after Liver Transplantation. HPB. 2021;23(Supplement 1):S100.	3
40	Kobayashi H, Joshita S, Akahane Y, Matsuzaki K, Yamada H, Aomura D, et al. Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project. PLoS ONE. 2021;16(8 August 2021):e0256711.	3
41	Koyama M, Yamazaki T, Joshita S, Ito A, Ono K, Watanabe T, et al. An autopsy case of primary biliary cholangitis with histological submassive hepatic necrosis caused by acute hepatitis e virus infection. Internal Medicine. 2021;60(12):1863-70.	5
42	Lok J, Agarwal K. Screening for hepatocellular carcinoma in chronic hepatitis b: An update. Viruses. 2021;13(7):1333.	2
43	Migita K, Nakamura M, Aiba Y, Kozuru H, Abiru S, Komori A, et al. Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis. PLoS ONE. 2021;15(12 December):e0238540.	7
44	Nagaoka K, Tanaka M, Tanaka Y. Mac-2 binding protein and its glycan isomer: Where does it come from? Where is it going? Hepatology research : the official journal of the Japan Society of Hepatology. 2021;51(10):1026-8.	2
45	Noro E, Matsuda A, Kyoutou T, Sato T, Tomioka A, Nagai M, et al. N-glycan structures of Wisteria floribunda agglutinin-positive Mac2 binding protein in the serum of patients with liver fibrosis. Glycobiology. 2021;31(10):1268-78.	1
46	Nozaki A, Chuma M, Hara K, Moriya S, Fukuda H, Numata K, et al. Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study. Medicine. 2021;100(12):e25110.	7
47	Osawa Y, Yoshio S, Aoki Y, Korenaga M, Imamura M, Oide T, et al. Blood angiopoietin-2 predicts liver angiogenesis and fibrosis in hepatitis C patients. BMC gastroenterology. 2021;21(1):55.	7
48	Sanityoso A, Hasan I, Lesmana CRA, Kurniawan J, Jasirwan COM, Nababan S, et al. Accuracy of mac-2-binding protein glycosylation isomer (M2BPGi) to assess liver stiffness in the treatment naive chronic hepatitis C patients in Indonesia. Journal of Gastroenterology and Hepatology. 2021;36(SUPPL 2):188-9.	3
49	Sato S, Tsuzura H, Kita Y, Ikeda Y, Kabemura D, Sato S, et al. Post-treatment serum Wisteria floribunda agglutinin-positive mac-2-binding protein level is a useful predictor of hepatocellular carcinoma development after hepatitis C virus eradication. JGH open : an open access journal of gastroenterology and hepatology. 2021;5(10):1203-9.	7

50	Shimada S, Kamiyama T, Kakisaka T, Orimo T, Nagatsu A, Asahi Y, et al. The impact of elastography with virtual touch quantification of future remnant liver before major hepatectomy. Quantitative imaging in medicine and surgery. 2021;11(6):2572-85.	7
51	Shinozaki S, Tahara T, Lefor AK, Ogura M. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study. Clinical and experimental hepatology. 2021;7(2):172-7.	7
52	Sulaiman AS, Hasan I, Hustrini NM, Gani RA, Lydia A, Hanifa RS. Diagnostic performance of mac-2-binding protein glycosylation isomer (M2BPGi) to assess liver stiffness in chronic hepatitis C patients with chronic kidney disease on hemodialysis. Journal of Gastroenterology and Hepatology. 2021;36(SUPPL 2):188.	3
53	Suzuki T, Matsuura K, Nagura Y, Iio E, Ogawa S, Fujiwara K, et al. Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection. PloS one. 2021;16(12):e0261878.	7
54	Tak KY, Jang B, Lee SK, Nam HC, Sung PS, Bae SH, et al. Use of M2BPGi in HCC patients with TACE. Journal of gastroenterology and hepatology. 2021;36(10):2917-24.	7
55	Takakusagi S, Sato K, Marubashi K, Kizawa K, Kosone T, Kakizaki S, et al. Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines. 2021;9(6).	7
56	Tamai H, Okamura J, Ohoshi T, Wakasaki H. Measurements of Serum Mac-2-Binding Protein Glycosylation Isomer and Shear Wave Velocity in Health Checkups Are Useful in Screening for Non-Alcoholic Steatohepatitis. Healthcare (Basel, Switzerland). 2021;9(5).	5
57	Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. Annals of laboratory medicine. 2021;41(1):16-24.	2
58	Tsuzura H, Kita Y, Ikeda Y, Kabemura D, Sato S, Amano N, et al. Post-treatment serum Wisteria floribunda agglutinin-positive mac-2-binding protein level is a useful predictor of hepatocellular carcinoma development after hepatitis C virus eradication. JGH Open. 2021;5(10):1203-9.	7
59	Umetsu S, Inui A, Sogo T, Fujisawa T. Usefulness of serum Wisteria floribunda agglutin-positive Mac-2 Binding Protein level in children with primary sclerosing cholangitis. Journal of Pediatric Gastroenterology and Nutrition. 2021;72(SUPPL 1):877.	3
60	Wu PS, Hsieh YC, Lee KC, Huang YH, Hou MC, Lin HC. Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients. PLoS ONE. 2021;16(10 October):e0258589.	7
61	Yamamura K, Beppu T, Sato N, Oda E, Kinoshita K, Yuki H, et al. Huge hepatocellular carcinoma with extrahepatic collateral arteries successfully treated by multidisciplinary treatment including laparoscopic devascularization: a case report. Clinical Journal of Gastroenterology. 2021;14(1):251-7.	7
62	Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. Ann Lab Med. 2021;41(1):16-24.	2
63	Kim M, Jun DW, Park H, Kang BK, Sumida Y. Sequential combination of FIB-4 followed by m2bpgi enhanced diagnostic performance for advanced hepatic fibrosis in an average risk population. Journal of Clinical Medicine. 2020;9(4):1119.	7
64	Ogawa M, Tsuchiya A, Watanabe T, Setsu T, Kimura N, Matsuda M, et al. Screening and follow-up of chronic liver diseases with understanding their etiology in clinics and hospitals. JGH open : an open access journal of gastroenterology and hepatology. 2020;4(5):827-37.	7

65	Saleh SA, Salama MM, Alhusseini MM, Mohamed GA. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World journal of gastroenterology. 2020;26(21):2864-76.	7
66	Ishida K, Namisaki T, Murata K, Fujimoto Y, Takeda S, Enomoto M, et al. Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. Journal of clinical medicine. 2020;9(11).	7
67	Joshita S, Yamashita Y, Sugiura A, Uehara T, Usami Y, Yamazaki T, et al. Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis. Journal of gastroenterology and hepatology. 2020;35(7):1208-14.	7
68	Ng E, Le AK, Nguyen MH, Wang SX. Early Multiplexed Detection of Cirrhosis using Giant Magnetoresistive Biosensors with Protein Biomarkers. ACS sensors. 2020;5(10):3049-57.	6
69	Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World journal of hepatology. 2020;12(5):220-9.	7
70	Silsirivanit A, Matsuda A, Kuno A, Tsuruno C, Uenoyama Y, Seubwai W, et al. Multi-serum glycobiomarkers improves the diagnosis and prognostic prediction of cholangiocarcinoma. Clinica chimica acta; international journal of clinical chemistry. 2020;510:142-9.	7
71	Alkhouri N, Noureddin M, Adams LA, Feldstein AE. The combination of serum mac-2-binding protein and cytokeratin 18 fragment levels accurately predict the presence of advanced NASH. Hepatology. 2020;72(1 SUPPL):947A-8A.	3
72	Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. International journal of molecular sciences. 2020;21(3).	2
73	Cho YY, Lhim H, Lee HW, Kim HJ. Real world efficacy of M2BPGi on diagnosing liver fibrosis in chronic hepatitis patients. Hepatology International. 2020;14(Supplement 1):S210.	3
74	Chuaypen N, Chittmittrapap S, Avihingsanon A, Tangkijvanich P. Dynamic changes of serum M2BPGi as a fibrosis marker of patients with HCV mono-infection and HCV/HIV co-infection receiving direct-acting anti-viral therapy. Journal of Hepatology. 2020;73(Supplement 1):S621-S2.	3
75	Chuaypen N, Chittmittraprap S, Avihingsanon A, Tangkijvanich P. Serum M2BPGi level as a novel fibrosis marker in treatmentnai ?e patients with HCV mono-infection and HCV/HIV coinfection. Hepatology International. 2020;14(Supplement 1):S139.	3
76	Dolgormaa G, Harimoto N, Ishii N, Yamanaka T, Hagiwara K, Tsukagoshi M, et al. Mac-2-binding protein glycan isomer enhances the aggressiveness of hepatocellular carcinoma by activating mTOR signaling. British journal of cancer. 2020;123(7):1145-53.	7
77	Enkhbayar U, Dambadarjaa D, Namdag B, Radnaa O. Prevalence of HBV and HCV in the 40-64 age population of Mongolia. Hepatology International. 2020;14(Supplement 1):S463.	7
78	Feng S, Wang Z, Zhao Y, Tao C. Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis. Scientific reports. 2020;10(1):10582.	2
79	Harimoto N, Araki K, Ishii N, Muranushi R, Hoshino K, Hagiwara K, et al. Predictors of Postoperative Ascites After Hepatic Resection in Patients With Hepatocellular Carcinoma. Anticancer research. 2020;40(8):4343-9.	7
80	Hayashi T, Tamaki N, Kurosaki M, Wang W, Okada M, Higuchi M, et al. Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients. Diagnostics (Basel, Switzerland). 2020;10(3).	7

81	Ichimoto K, Fujisawa T, Shimura M, Fushimi T, Tajika M, Matsunaga A, et al. Two cases of a non-progressive hepatic form of glycogen storage disease type IV with atypical liver pathology. Molecular genetics and metabolism reports. 2020;24:100601.	7
82	Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clinical and molecular hepatology. 2020;26(3):261-79.	2
83	Ishikawa T, Sasaki R, Nishimura T, Iwamoto T, Takami T, Yamasaki T, et al. Improved Hepatic Reserve and Fibrosis in a Case of "Portal-Systemic Liver Failure" by Portosystemic Shunt Occlusion. The American journal of case reports. 2020;21:e921236.	7
84	jRCTs J. PORTRAIT study. https://trialsearchwhoint/Trial2aspx?TrialID=JPRN-jRCTs041200011. 2020.	3
85	Kamada Y, Morishita K, Koseki M, Nishida M, Asuka T, Naito Y, et al. Serum Mac-2 Binding Protein Levels Associate with Metabolic Parameters and Predict Liver Fibrosis Progression in Subjects with Fatty Liver Disease: A 7-Year Longitudinal Study. Nutrients. 2020;12(6).	5
86	Kawin T, Tanita S, Prakasit S, Churairat K, Wattana S. Comparison of MAC-2 binding protein glycosylation isomer as a non-invasive biomarker for probing liver disease. Hepatology International. 2020;14(Supplement 1):S213-S4.	3
87	Kikuchi M. Changes in amino acid composition (Fisher ratio and BTR) with the progress of liver cirrhosis. Hepatology International. 2020;14(Supplement 1):S206-S7.	7
88	Kikukawa K, Uchida-Kobayashi S, Tamori A, Yoshida K, Kotani K, Motoyama H, et al. Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients. Annals of hepatology. 2020;19(4):367-72.	7
89	Kim HS, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Serum Wisteria floribunda agglutinin-positive human mac-2 binding protein level predicts recurrence of hepatitis b virus-related hepatocellular carcinoma after curative resection. Clinical and Molecular Hepatology. 2020;26(1):33-44.	7
90	Kim MM, Jun D, Sohn JH, An J, Yoon E, Jeong JY, et al. Diagnostic accuracy of WFA+ - M2BP for significant hepatic fibrosis determined by MR elastography. Journal of Hepatology. 2020;73(Supplement 1):S509-S10.	3
91	Kon K, Uchiyama A, Fukuhara K, Morinaga M, Fukada H, Nakadera E, et al. Involvement of carnitine metabolism in covert hepatic encephalopathy. Hepatology. 2020;72(1 SUPPL):1072A-3A.	7
92	Lin J, Ko CJ, Hung YJ, Lin PY, Lin KH, Hsieh CE, et al. Prognostic Role of Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Level in Early Stage Hepatocellular Carcinoma. Scientific reports. 2020;10(1):5651.	7
93	Murata A, Amano N, Tsuzura H, Tomishima K, Sato S, Matsumoto K, et al. On-treatment serum mac-2 binding protein glycosylation isomer (M2bpgi) level and risk of hepatocellular carcinoma development in patients with chronic hepatitis b during nucleot(s)ide analogue therapy. International Journal of Molecular Sciences. 2020;21(6):2051.	7
94	Nababan SHH, Kalista KF, Jasirwan COM, Kurniawan J, Lesmana CR, Sulaiman AS, et al. Kinetics of plasma mac-2 binding protein glycosylation isomer level in hepatitis c patients with cirrhosis. Hepatology International. 2020;14(Supplement 1):S106-S7.	3
95	Nababan SHH, Raharjo M, Kalista KF, Jasirwan COM, Kurniawan J, Lesmana CR, et al. Non-invasive parameters and plasma Mac-2 binding protein glycosylation isomer level as predictors of high-risk esophageal varices in cirrhosis. Hepatology International. 2020;14(Supplement 1):S407.	7

96	Nah EH, Cho S, Kim S, Kim HS, Cho HI. Diagnostic performance of Mac-2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups. Journal of Clinical Laboratory Analysis. 2020;34(8):e23316.	5
97	Nakagawa M, Nawa N, Takeichi E, Shimizu T, Tsuchiya J, Sato A, et al. Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. Journal of Gastroenterology. 2020;55(10):990-9.	7
98	Nghia CH, Truc ND. Establishing the use of serum mac 2 binding protein glycosylation isomer to provide non-invasive profiling of liver disease. Hepatology International. 2020;14(Supplement 1):S452-S3.	3
99	Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, et al. Walking speed: Japanese data in chronic liver diseases. Journal of Clinical Medicine. 2020;9(1):166.	6
100	Nishimura T, Fujiwara A, Ueshima T, Kishino K, Shimono Y, Koriyama T, et al. Clinical usefulness of dispersion using shear wave elastography for the chronic hepatitis patients. Hepatology. 2020;72(1 SUPPL):769A.	3
101	Ogasawara N, Saitoh S, Akuta N, Sezaki H, Suzuki F, Fujiyama S, et al. Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C. Hepatology research : the official journal of the Japan Society of Hepatology. 2020;50(4):426-38.	7
102	Osawa L, Tamaki N, Kurosaki M, Kirino S, Watakabe K, Wang W, et al. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not alpha-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. International journal of molecular sciences. 2020;21(10).	7
103	Ozeki I, Nakajima T, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, et al. Predictors of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting antiviral treatment: relationship with serum zinc. Journal of clinical biochemistry and nutrition. 2020;66(3):245-52.	7
104	Park H, Jun DW, Park HK, Kim M. Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes. Annals of Translational Medicine. 2020;8(23):1583.	5
105	Radnaa O, Idkhuu A, Enkhbayar U, Sevjid B, Sonomtseren S, Baatarkhuu O. Functional abnormalities of the liver in diabetic patients with and without viral hepatitis C in Mongolia. Hepatology International. 2020;14(Supplement 1):S129-S30.	7
106	Sartika KD, Setiawan SI, Leonard EN, Saputra IY, Tendean M, Kurniawan J. Serum Mac-2-binding protein glycosylation isomer (M2bpgi) as a predictor of hepatocellular carcinoma development in chronic hepatitis B patients: A systematic review. Hepatology International. 2020;14(Supplement 1):S245-S6.	2
107	Sato S, Tsuzura H, Genda T. Post-treatment wisteria floribunda agglutinin-positive mac-2-binding protein is a useful predictor of hepatocellular carcinoma development after hepatitis C virus eradication. Journal of Hepatology. 2020;73(Supplement 1):S624-S5.	7
108	Sato S, Tsuzura H, Genda T. Wisteria floribunda agglutinin-positive Mac-2-binding protein is a useful prediction of hepatocellular carcinoma development after hepatitis C virus eradication. Hepatology International. 2020;14(Supplement 1):S141.	7
109	Seike T, Komura T, Shimizu Y, Omura H, Kumai T, Kagaya T, et al. The Serum Mac-2-binding Protein Glycosylation Isomer Dynamics in Acute Liver Injury. Internal medicine (Tokyo, Japan). 2020;59(13):1581-8.	5

110	Su TH, Peng CY, Tseng TC, Yang HC, Liu CJ, Liu CH, et al. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. Journal of Infectious Diseases. 2020;221(4):589-97.	7
111	Sulaiman AS, Hustrini NM, Hanifa RS. Serum mac-2-binding protein glycosylation isomer M2BPGi compared to transient elastography to predict liver stiffness in hepatitis C patients on hemodialysis. Hepatology International. 2020;14(Supplement 1):S118.	3
112	Sumida Y, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, et al. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics. 2020;10(8):579.	2
113	Takakusagi S, Takagi H, Yokoyama Y, Marubashi K, Kizawa K, Kosone T, et al. Successful treatment with glecaprevir/pibrentasvir for chronic hepatitis C complicated by primary biliary cholangitis. Clinical Journal of Gastroenterology. 2020;13(5):896-901.	7
114	Takamura M, Sakamaki A, Arao Y, Setsu T, Kamimura H, Yokoo T, et al. Daily Monitoring of Serum Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein Is Useful for Predicting Therapeutic Effect of Tolvaptan in Cirrhotic Ascites. The Tohoku journal of experimental medicine. 2020;252(4):287-96.	7
115	Takatsuki M, Yamasaki K, Natsuda K, Hidaka M, Ono S, Adachi T, et al. Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients. Hepatology research : the official journal of the Japan Society of Hepatology. 2020;50(4):419-25.	7
116	Takemura K, Takizawa E, Tamori A, Nakamae M, Kubota H, Uchida-Kobayashi S, et al. Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. International journal of molecular sciences. 2020;21(12).	7
117	Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Kirino S, Inada K, et al. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. International journal of molecular sciences. 2020;22(1).	5
118	Tan SJ, Hoang NT. Non-invasive probing of liver disease using novel mac 2 binding protein glycosylation isomer comparing with FibroTest and FIB-4. Hepatology International. 2020;14(Supplement 1):S207.	3
119	Tovuu LO. HDV viral load related liver fibrosis patients clinical evaluation based on M2BPGi level in serum. Hepatology International. 2020;14(Supplement 1):S206.	3
120	Tseng TC, Peng CY, Hsu YC, Su TH, Wang CC, Liu CJ, et al. Baseline M2BPGi level stratifies risks of hepatocellular carcinoma in chronic hepatitis B patients with oral antiviral therapy. Hepatology International. 2020;14(Supplement 1):S15-S6.	3
121	Tseng TC, Peng CY, Hsu YC, Su TH, Wang CC, Liu CJ, et al. Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. Liver Cancer. 2020;9(2):207-20.	7
122	Tsuji S, Uchida Y, Uemura H, Kouyama JI, Naiki K, Nakao M, et al. Involvement of portosystemic shunts in impaired improvement of liver function after direct-acting antiviral therapies in cirrhotic patients with hepatitis C virus. Hepatology Research. 2020;50(4):512-23.	7
123	Volkova NN, Ibadullaeva NS, Asilova MU, Musabaev EI. Significance of serum wfa+-m2bp level as a marker of liver fibrosis in patients with chronic hepatitis c. Infektsionnye Bolezni. 2020;18(4):80-4.	4
124	Yatsuhashi H, Yamasaki K. [M2BPGi is a new glycol-biomarker to predict liver fibrotic stage]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology. 2020;117(1):20-9.	4

125	Altantuya I, Dashchirev M-o, Baasankhuu E, Uranbaigali E, Oidov B. Functional Abnormalities of the Liver in Diabetic Patients with and without Viral Hepatitis C in Mongolia. 춘·추계 학술대회 (KASL). 2020;2020(1):291-2.	3
126	Hyunjoon P, Gyuwon L, Joon Ho J, Kwang II S, Sang Uk L, Byung Cheol Y, et al. Clinical Usefulness of Serum M2BPGi Levels on Identifying Liver Cirrhosis in Patients with Chronic Liver Disease. 춘·추계 학술대회 (KASL). 2020;2020(1):234-5.	3
127	Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2020;26(3):261-79.	2
128	Kwon Yong T, Jeong Won J. M2BPGi as a Prognostic Factor for HCC Patients Receiving TACE: Analysis in Comparison with HAP Score. 춘·추계 학술대회 (KASL). 2020;2020(1):219-.	3
129	Munkhchuluun B, Dashchirev M-o, Baasankhuu E, Oidov B. Prevalence of HBV and HCV in Mongolia. 춘·추계 학술대회 (KASL). 2020;2020(1):290-.	3
130	Suhyun P, Dae Won J, Seungmin L, Jihyun A, Joo Hyun S. Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population. 춘·추계 학술대회 (KASL). 2020;2020(1):136-.	3
131	Young Youn C, Hansol L, Hyun Woong L, Hyung Jun K. Real-World Efficacy of M2BPGi on Diagnosing Liver Fibrosis in Chronic Hepatitis Patients. 춘·추계 학술대회 (KASL). 2020;2020(1):140-.	3
132	김혜수, 김승업, 김범경, 박준용, 김도영, 안상훈, et al. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. Clinical and Molecular Hepatology. 2020;26(1):33-44.	7
133	조수민, 이규원, 박현준, 서광일, 이상욱, 윤병철, et al. Clinical usefulness of Serum M2BPGi on Identifying Liver Cirrhosis in Patients with Liver disease. 대한내과학회 추계학술발표논문집. 2020;2020(1):148-.	3
134	Mak LY, Wong DKH, Seto WK, Ning Q, Cheung KS, Fung J, et al. Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. Hepatology International. 2019;13(2):148-56.	7
135	Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, et al. Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. Scientific reports. 2019;9(1):10109.	7
136	Liu T, Sun Y, Zhou J, Yang F, Zou X, Wang L, et al. On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add-on therapy. Journal of medical virology. 2019;91(8):1499-509.	7
137	Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, et al. Combined albumin-bilirubin grade and Mac-2 binding protein glycosylation isomer as a useful predictor in compensated liver cirrhosis. Medicine. 2019;98(50):e18366.	7
138	Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, et al. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. Journal of viral hepatitis. 2019;26(7):893-9.	7
139	Ueno T, Kodama T, Noguchi Y, Nomura M, Saka R, Takama Y, et al. Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis. Pediatric surgery international. 2019;35(10):1065-70.	7
140	Akahoshi Y, Nakasone H, Kawamura K, Kusuda M, Kawamura S, Takeshita J, et al. Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT. Blood Advances. 2019;3(21):3287-96.	5

141	Akuta N, Suzuki F, Sezaki H, Fujiyama S, Kawamura Y, Hosaka T, et al. Complex association of virus- and host-related factors with hepatocellular carcinoma rate following hepatitis C virus clearance. Journal of Clinical Microbiology. 2019;57(1):e01463.	7
142	Akuta N, Suzuki F, Sezaki H, Fujiyama S, Kawamura Y, Hosaka T, et al. Complex association of virus-and host-related factors with treatment resistance to daas regimens and HCC following HCV eradication. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):916A.	7
143	Arai T, Atsukawa M, Tsubota A, Yoshida Y, Okubo T, Iwashita A, et al. Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):1364A-5A.	7
144	Bando T, Shibuya K, Yoshioka I, Fujii T. Liver fibrosis after pylorus-preserving pancreatoduodenectomy. Pancreas. 2019;48(10):1406.	3
145	Choi R, Oh Y, Lee S, Lee SG. Evaluation of the Serum Mac-2 Binding Protein Glycosylation Isomer Test used for Diagnosis and Monitoring of Liver Fibrosis and the Correlation of Mac-2 Binding Protein Glycosylation Isomer with Hemoglobin A1c. Clinical laboratory. 2019;65(1).	7
146	Chuaypen N, Chittmittraprap S, Avihingsanon A, Tangkijvanich P. Serum M2BPGi reduction in patients with HCV monoinfection and HCV/HIV co-infection who received direct-acting anti-viral therapy. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):985A.	3
147	Eso Y, Takai A, Takahashi K, Ueda Y, Taura K, Marusawa H, et al. Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma. Cancers. 2019;11(3).	7
148	Gantumur D, Ishii N. WFA+ MAC-2 binding protein (M2BPGi) enhance aggressiveness of hepatocellular carcinoma via activation of mtor signaling. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):1203A-4A.	7
149	Iio E, Matsuura K, Shimada N, Atsukawa M, Takaguchi K, Eguchi Y, et al. Predictors of hepatocellular carcinoma development after eradication of hepatitis C virus based on TLL1 variant, AFP and fib 4 index. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):322A-3A.	7
150	Imai D, Maeda T, Wang H, Sanefuji K, Kayashima H, Yoshiya S, et al. Elevation of Mac-2 binding protein glycosylation isomer after hepatectomy is associated with post-hepatectomy liver failure, total Pringle time, and renal dysfunction. Annals of gastroenterological surgery. 2019;3(5):515-22.	7
151	Imanaka S, Shibasaki Y. A study of Mac-2 Binding Protein Glycosylation Isomer (M2BPGI), A Serum Marker of liver Fibrosis, in Patients Undergoing Maintenance Hemodialysis. Therapeutic Research. 2019;40(4):323-7.	4
152	Ishidalr H, Suetsugu A, Furuta N, Nohisa Y, Takemura M, Saito K, et al. Changes of liver fibrosis markers in patients with treatment by antiviral therapy. Japanese Journal of Clinical Chemistry. 2019;48(2):137-43.	4
153	Ishii N, Harimoto N, Araki K, Muranushi R, Hoshino K, Hagiwara K, et al. Preoperative Mac-2 binding protein glycosylation isomer level predicts postoperative ascites in patients with hepatic resection for hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology. 2019;49(12):1398-405.	7
154	Joshita S, Umemura T, Yamashita Y, Sugiura A, Yamazaki T, Fujimori N, et al. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis. Hepatology research : the official journal of the Japan Society of Hepatology. 2019;49(10):1236-43.	6
155	Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, et al. Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. Hepatology Communications. 2019;3(4):493-503.	7

156	Kanno M, Kawaguchi K, Honda M, Horii R, Takatori H, Shimakami T, et al. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis. Journal of Gastroenterology. 2019;54(6):549-57.	7
157	Kasai A, Mawatari S, Taniyama O, Ijuin S, Sakae H, Tabu K, et al. Usefulness of shear wave elastography before and after direct-acting antiviral treatment for hepatitis C virus. United European Gastroenterology Journal. 2019;7(8 Supplement):770-1.	7
158	Kawaguchi K, Honda M, Orita N, Kanno M, Horii R, Nio K, et al. Serum aldo-keto reductase family 1 member b10 predicts HBV-related hepatocellular carcinoma during nucleos(t)ide analogue treatment. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):417A.	7
159	Kimura Y, Taura K, Nam NH, Uemoto Y, Yoshino K, Wada S, et al. USEFULNESS OF MAC-2 BINDING PROTEIN GLYCOSYLATION ISOMER FOR EVALUATING GRAFT STATUS AFTER LIVER TRANSPLANTATION. Gastroenterology. 2019;156(6 Supplement 1):S-1327.	3
160	Kobayashi T, Ogawa K, Furukawa JI, Hanamatsu H, Nakai M, Sho T, et al. Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):1079A.	7
161	Kugiyama Y, Yamasaki K, Beppu A, Bekki S, Suehiro T, Hashimoto S, et al. Serum myostatin is associated not only with survival rate but also with risk of developing hepatocellular carcinoma in patients with liver cirrhosis. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):1249A-50A.	7
162	Lin B, Ma Y, Wu S, Liu Y, Liu L, Wu L. Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis. Omics : a journal of integrative biology. 2019;23(4):181-9.	2
163	Lin J, Chen YL. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts overall survival in early stage hepatocellular carcinoma. HPB. 2019;21(Supplement 2):S366-S7.	7
164	Lin YJ, Huang YH, Chen LC, Hu HH, Liu J, Jen CL, et al. Combined Use of WFA(1)-M2BP and AFP-L3 for the prediction of HCV-related hepatocellular carcinoma development. Hepatology International. 2019;13(Supplement 1):S156.	7
165	Mak LY, Ko M, To E, Wong DKH, Ma JHC, Hui TLY, et al. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. Journal of Gastroenterology and Hepatology (Australia). 2019;34(10):1817-23.	7
166	Mak LY, To WP, Fung J, Wong DKH, Liu F, Seto WK, et al. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. World Journal of Gastroenterology. 2019;25(11):1398-408.	7
167	Murakawa M, Asahina Y, Inoue E, Nakagawa M, Tsuchiya J, Sato A, et al. The association of serum IFN-lambda3 levels with liver fibrosis and hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents. Journal of Hepatology. 2019;70(1):e744.	7
168	Nakagawa M, Asahina Y, Tsuchiya J, Sato A, Tsunoda T, Miyoshi M, et al. Impact of HCV clearance on HCC development and patient survival: Propensity score-matched analysis of an ongoing database of 2173 CHC patients. Journal of Hepatology. 2019;70(1):e744-e5.	7
169	Numao H, Shimaya K, Kakizaki F, Sawada Y, Saito K, Araki Y, et al. Diagnostic accuracy of ultrasound two-dimensional shear wave elastography and magnetic resonance elastography for assessing liver fibrosis in patients infected with the hepatitis c virus. Journal of Gastroenterology and Hepatology. 2019;34(Supplement 3):261.	3

170	Osawa L, Tamaki N, Kurosaki M, Kirino S, Yamashita K, Hayakawa Y, et al. Serum wisteria floribunda agglutinin-positive MAC-2 binding protein after eradication of hepatitis C virus is superior to alpha-fetoprotein to define patients at high and low risk of hepatocellular carcinoma development during the long-term course. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):320A.	3
171	Ozeki I, Suii H, Tatsumi R, Yamaguchi M, Kimura M, Arakawa T, et al. The development of HCC in chronic hepatitis B patients with nucleos (t)ide analogs: Focus on hepatitis B surface antigen and core-related antigen. Journal of Hepatology. 2019;70(1):477.	7
172	Pham T, Tan Ho D, Nguyen T, Nguyen TTB. Usefulness of MAC2 binding protein glycosylation isomer in non-invasive probing of liver disease in the vietnamese population. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):1010A.	3
173	Samy A, Saleh S, Salama M, Abdelrahman G, Alhusseini M. Mac-2 binding protein glycan isomer is a reliable marker for the assessment of liver fibrosis grade in chronic hepatitis C patients treated with direct acting anti virals. United European Gastroenterology Journal. 2019;7(8 Supplement):211.	3
174	Shimaya K, Numao H, Araki Y, Hanabata N, Munakata M, Fukuda S. Noninvasive diagnosis of fibrosis in the patients with hepatitis C virus infection treated with direct-anting antivirals. Journal of Gastroenterology and Hepatology. 2019;34(Supplement 3):212.	3
175	Sugiura T, Dohi Y, Takase H, Yamashita S, Tsuzuki Y, Ogawa S, et al. Factors associated with longitudinal changes in serum concentrations of Mac-2 binding protein: A prospective 3-year observational study. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2019;29(12):1337-44.	5
176	Sung JH, Uojima H, Hidaka H, Tanaka Y, Wada N, Kubota K, et al. Risk factors for loss of skeletal muscle mass in patients with cirrhosis. Hepatology research : the official journal of the Japan Society of Hepatology. 2019;49(5):550-8.	7
177	Takagi T, Suzuki R, Sugimoto M, Konno N, Sato Y, Irie H, et al. Non-specific elevation of serum Mac-2 binding protein glycosylation isomer levels in patients with biliary disease. Molecular and clinical oncology. 2019;10(1):168-72.	7
178	Tamaki N, Higuchi M, Kurosaki M, Kaneko S, Yasui Y, Tsuchiya K, et al. Prediction of hepatocellular carcinoma development using liver stiffness after sustained virological responses by magnetic resonance elastography in patients with chronic hepatitis C. Journal of Hepatology. 2019;70(1):e750.	3
179	Tovuu LO, Yanjiv D, Bayarsaikhan E. Accuracy of M2BPGi, compared with other non-invasive analysis of liver fibrosis in patients with hepatitis D. Journal of Gastroenterology and Hepatology. 2019;34(Supplement 3):542.	3
180	Uchiyama H, Shirabe K, Bekki Y, Toshima T, Harimoto N, Ikegami T, et al. Peritransplant kinetics of Mac-2-binding protein glycosylation isomer levels in living donor liver transplantation: its implication of posttransplant small-for-size syndrome. Translational gastroenterology and hepatology. 2019;4:41.	7
181	Uehara D, Naganuma A, Hoshino T, Taira T, Murakami T, Sohara N, et al. EFFECT OF DIRECT-ACTING ANTIVIRALS ON SERUM LIPID PROFILES AND BODY COMPOSITION OF CHRONIC HEPATITIS C PATIENTS: A RETROSPECTIVE STUDY. Clinical Nutrition. 2019;38(Supplement 1):S79.	7
182	Ueno T, Kodama T, Noguchi Y, Nomura M, Saka R, Takama Y, et al. Clinical implications of serum MAC-2 binding protein in regular follow up after pediatric living donor liver transplantation. American Journal of Transplantation. 2019;19(Supplement 3):532.	3

183	Uojima H, Hidaka H, Shibuya A. Wisteria floribunda agglutinin-positive human MAC-2 binding protein as a useful clinical predictor for hepatic function in patients with cirrhosis. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):191A-2A.	3
184	Watakabe K, Tamaki N, Kirino S, Osawa L, Wan W, Okada M, et al. Non-invasive prediction of gastroesophageal varies by serum wisteria floribunda agglutinin positive Mac-2 binding protein and FIB-4 index in chronic hepatitis C. Journal of Hepatology. 2019;70(1):e751-e3.	7
185	Yamada N, Mizuta K. Advanced assessment of serum Mac-2 binding protein glycosylation isomer in patients with biliary atresia. Journal of gastroenterology. 2019;54(2):204-5.	2
186	Yamauchi R, Takata K, Shinagawa Y, Tanaka T, Fukuda H, Fukuda S, et al. Hepatocellular carcinoma arising in a non-cirrhotic liver with secondary hemochromatosis. Internal Medicine. 2019;58(5):661-5.	7
187	Yasui Y, Abe T, Kurosaki M, Matsunaga K, Higuchi M, Tamaki N, et al. Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. Hepatology research : the official journal of the Japan Society of Hepatology. 2019;49(1):33-41.	7
188	Yokoyama S, Ishigami M, Honda T, Kuzuya T, Ishizu Y, Ito T, et al. Non-invasive screening for detecting esophagogastric varices in children with biliary atresia. Hepatology v70 suppl1 2019. 2019;70(Supplement 1):200A.	7
189	Chuaypen N, Chittmittraprap S, Pinjaroen N, Sirichindakul B, Poovorawan Y, Tanaka Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology. 2018;48(11):872-81.	7
190	문희원, 박미경, 허미나, 김한아, 최원혁, 윤여민. Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases. Annals of Laboratory Medicine. 2018;38(4):331-7.	7
191	Wei B, Feng S, Chen E, Li D, Wang T, Gou Y, et al. M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with Hepatitis B virus infection. Journal of clinical laboratory analysis. 2018;32(2).	7
192	Inoue T, Tsuzuki Y, Iio E, Shinkai N, Matsunami K, Fujiwara K, et al. Clinical Evaluation of Hepatocarcinogenesis and Outcome Using a Novel Glycobiomarker Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA+-M2BP) in Chronic Hepatitis C with Advanced Fibrosis. Japanese journal of infectious diseases. 2018;71(3):177-83.	7
193	Uojima H, Hidaka H, Tanaka Y, Inoue T, Onoue M, Wada N, et al. Wisteria floribunda agglutinin-positive human Mac-2 binding protein in decompensated cirrhosis. Journal of gastroenterology and hepatology. 2018;33(11):1889-96.	7
194	Xu WP, Wang ZR, Zou X, Zhao C, Wang R, Shi PM, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein evaluates liver function and predicts prognosis in liver cirrhosis. Journal of digestive diseases. 2018;19(4):242-53.	7
195	Akahoshi Y, Nakasone H, Kawamura K, Sato M, Kikuchi M, Misaki Y, et al. Increased MAC 2-binding protein glycan isomer (M2BPGI) would predict late non-relapse mortality after allogeneic hematopoietic cell transplantation. Blood. 2018;132(Suppl. 1).	5
196	Akuta N, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, et al. Core AA70 substitution and post-WFA+M2BP are the important predictors of hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens. Hepatology. 2018;68(Supplement 1):345A-6A.	7

197	Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, et al. Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis (PLoS ONE (2018) 13:8 (e0202226) DOI: 10.1371/journal.pone.0202226). PLoS ONE. 2018;13(10):e0205541.	2
198	Anonymous. 27th Annual Conference of APASL. Hepatology International. 2018;12(2).	2
199	Chen B. Letter to the editor: Increased levels of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in idiopathic pulmonary fibrosis. Respiratory medicine. 2018;145:229.	2
200	Cho SY, Hur M. Mac-2 Binding Protein Glycosylation Isomer: Emerging Non-Invasive Serum Marker for Liver Fibrosis. Annals of laboratory medicine. 2018;38(4):289-90.	2
201	Chuaypen N, Tanaka Y, Tangkijvanich P. Serum WFA+-M2BP level as a diagnostic marker of HBV-related HCC: A case-control study. Journal of Hepatology. 2018;68(Supplement 1):S487-S8.	3
202	Eso Y, Takai A, Taura K, Takahashi K, Ueda Y, Marusawa H, et al. Association of Mac-2-binding protein glycosylation isomer level with nutritional status in chronic liver disease. Journal of gastroenterology and hepatology. 2018.	7
203	Gantumur D, Araki K, Hagiwara K, Yamanaka T, Ishii N, Tsukagoshi M, et al. Functional analysis of WFA+ Mac-2 Binding Protein (M2BPGi) in hepatocellular carcinoma in vitro. Cancer Science. 2018;109(Supplement 2):376.	1
204	Hsu YC, Jun T, Huang YT, Yeh ML, Lee CL, Ogawa S, et al. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics. 2018;48(10):1128-37.	7
205	Hsu YC, Jun T, Huang YT, Yeh ML, Lin JT, Yu ML, et al. Serial changes in serum levels of MAC-2 binding protein glycosylation isomer and risk of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(T)ide analogues. Hepatology. 2018;68(Supplement 1):230A-1A.	7
206	Hsu YC, Jun T, Yeh ML, Huang YT, Yu ML, Nguyen M, et al. Changes in serum levels of the novel mac-2 binding protein glycosylation isomer and risk of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleos(t)ide analogues. Journal of Hepatology. 2018;68(Supplement 1):S496-S8.	7
207	Hsu YC, Jun T, Yeh ML, Huang YT, Yu ML, Nguyen MH, et al. CHANGES IN SERUM LEVELS OF THE NOVEL MAC-2 BINDING PROTEIN GLYCOSYLATION ISOMER (M2BPGI) AND RISK OF HEPATOCELLULAR CARCINOMA (HCC) AMONG CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH NUCLEOS(T)IDE ANALOGUES (NA). Gastroenterology. 2018;154(6 Supplement 1):S-1230.	7
208	Inoue T, Kanda R, Ohike T, Ohhashi M, Sato S, Goto T, et al. Diagnostic value of the serum biomarker MAC-2 binding protein glycan isomer (M2BPGI) for liver fibrosis in relation to fibrosis etiology and patient gender. Hepatology. 2018;68(Supplement 1):621A.	3
209	Iwata T, Inoue J, Akahane T, Kakazu E, Ninomiya M, Takai S, et al. Predictive factors of hepatocellular carcinoma after direct-acting antivirals therapy in chronic hepatitis C patients: A multicenter study. Hepatology. 2018;68(Supplement 1):352A-3A.	7
210	Jang SY, Tak WY, Park SY, Kweon YO, Lee YR, Jeong B, et al. The diagnostic efficacy of M2BPGi for liver fibrosis in HCC and NAFLD patients. Liver Cancer. 2018;7(Supplement 1):86-7.	3
211	Joshita S, Umemura T, Usami Y, Sugiura A, Yamazaki T, Fujimori N, et al. Autotaxin is a non-invasive biomarker for estimating chronic liver disease status. Journal of Gastroenterology and Hepatology. 2018;33(Supplement 4):216.	7
212	Joshita S, Umemura T, Usami Y, Yamashita Y, Norman GL, Sugiura A, et al. Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis. Scientific reports. 2018;8(1):8159.	7

213	Jprn U. Analysis of clinical effects and safety of entecavir treatment to chronic hepatitis B patients; multicenter pilot study. https://trialsearchwhoint/Trial2aspx?TrialID=JPRN-UMIN000030845. 2018.	9
214	Jun T, Tanaka Y, Hsu YC, Nguyen M, Yu ML. Using Wisteria floribunda agglutinin-positive Mac2-binding protein in combination with the FIB-4 index to predict significant liver fibrosis. Journal of Hepatology. 2018;68(Supplement 1):S650-S1.	3
215	Jun T, Yu ML, Hsu YC, Tanaka Y, Nguyen M. Performance of Wisteria floribunda agglutinin-positive Mac2-binding protein as an HCC biomarker in an ethnically diverse cohort of patients with chronic HBV and HCV. Journal of Hepatology. 2018;68(Supplement 1):S439.	3
216	Jun T, Yu ML, Hsu YC, Tanaka Y, Nguyen MH. Performance of Wisteria Floribunda Agglutinin Positive Mac2-Binding Protein as an HCC Biomarker in an Ethnically Diverse Cohort of Patients with Chronic HBV and HCV. Gastroenterology. 2018;154(6 Supplement 1):S-1231.	3
217	Kanno M, Kawaguchi K, Honda M, Horii R, Takatori H, Kitamura K, et al. Elevation of serum aldo-keto reductase family 1 member B10 is associated with advanced liver fibrosis in non-alcoholic steatohepatitis. Hepatology. 2018;68(Supplement 1):1312A-3A.	7
218	Kawaguchi K, Honda M, Ohta H, Terashima T, Shimakami T, Arai K, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B. Journal of Gastroenterology. 2018;53(6):740-51.	7
219	Kawanaka M, Nishinio K, Ishii K, Urata N, Tanikawa T, Nakamura J, et al. Combination of shear-wave elastography and liver fibrosis markers predicts severe fibrosis in patients with non-alcoholic steatohepatitis. Hepatology. 2018;68(Supplement 1):1293A-4A.	3
220	Kawanaka M, Tomiyama Y, Hyogo H, Koda M, Shima T, Tobita H, et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Hepatology research : the official journal of the Japan Society of Hepatology. 2018;48(7):521-8.	7
221	Lin YJ, Chang CL, Chen LC, Hu HH, Liu J, Korenaga M, et al. A Glycomarker for Short-term Prediction of Hepatocellular Carcinoma: A Longitudinal Study With Serial Measurements. Clinical and Translational Gastroenterology. 2018;9(9):183.	7
222	Mak LY, Seto WK, Cheung KS, Fung YYJ, Wong D, Lai CL, et al. Serum Mac-2-binding protein glycosylation isomer in assessing liver fibrosis in chronic hepatitis B infection. Journal of Hepatology. 2018;68(Supplement 1):S496.	3
223	Mak LY, Wong DKH, Seto WK, Cheung KS, Fung J, Lai CL, et al. High serum Mac-2-binding protein glycosylation isomer (M2BPGi) level was associated with incident hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. Hepatology. 2018;68(Supplement 1):864A.	7
224	Matsuura K, Aizawa N, Enomoto H, Nishiguchi S, Toyoda H, Kumada T, et al. Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C. Open forum infectious diseases. 2018;5(11):ofy268.	7
225	Migita K, Horai Y, Kozuru H, Koga T, Abiru S, Yamasaki K, et al. Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis. Medicine. 2018;97(50):e13450.	7
226	Mizuno K, Haga H, Okumoto K, Tomita K, Nishina T, Saito T, et al. Hepatic fibrosis rather than inflammation affects the intrahepatic distribution of nerve fibers in the diseased liver. Hepatology. 2018;68(Supplement 1):1129A-30A.	7

227	Murata A, Genda T, Sato S. On-treatmant serum wisteria fioribunda agglutinin-positive Mac-2 binding protein level and risk of hepatocellular carcinoma development in patients with chronic hepatitis B during nucleot(s)ide analog therapy. Journal of Hepatology. 2018;68(Supplement 1):S524-S5.	7
228	Nagata H, Nakagawa M, Asahina Y. Reply to: "Imaging Basis of AFP and WFA+M2BP as Indicators of the risk of HCC after SVR". Journal of hepatology. 2018;68(3):607-8.	2
229	Nakagawa M, Asahina Y, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, et al. Post-treatment M2BPGI level is useful for predicting HCC occurrence and recurrence after viral eradication in chronic hepatitis C patients. Hepatology. 2018;68(Supplement 1):398A.	7
230	Nakai M, Suda G, Ogawa K, Suzuki K, Nakamura A, Ohara M, et al. Higher wisteria floribunda agglutinin-positive Mac-2 binding protein (M2BPGi) not M2BP and pre-sarcopenia are prognostic and recurrence markers of primary hepatocellular carcinoma treated by RFA in HCV-negative and hcveradicated patients. Hepatology. 2018;68(Supplement 1):843A-4A.	7
231	Narimatsu H, Sato T. Wisteria floribunda agglutinin positive glycobiomarkers: a unique lectin as a serum biomarker probe in various diseases. Expert review of proteomics. 2018;15(2):183-90.	2
232	Ninomiya M, Inoue J, Kakazu E, Iwata T, Takai S, Nakamura T, et al. The FIB4 index and M2BPGi are the independent risk factors for recurrence after radiofrequency ablation for hepatocellular carcinoma. Hepatology. 2018;68(Supplement 1):851A-2A.	7
233	Nozaki A, Chuma M, Hara K, Moriya S, Fukuda H, Numata K, et al. Effect of ledipasvir/sofosbuvir or sofosbuvir+ribavirin therapy on liver fibrosis in japanese patients with hepatitis C virus infection: Results of a multi-centre prospective observational study. Hepatology. 2018;68(Supplement 1):395A-6A.	7
234	Numao H, Shimaya K, Hasui K, Igarashi K. Noninvasive diagnosis of fibrosis in the patients with hepatitis C virus infection treated with direct-acting antivirals. Journal of Hepatology. 2018;68(Supplement 1):S547.	3
235	Ogata F, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, et al. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens. Journal of Medical Virology. 2018;90(6):1087-93.	7
236	Ozeki I, Suii H, Tatsumi R, Yamaguchi M, Kimura M, Arakawa T, et al. Recurrence of hepatocellular carcinoma in patients with a history of HCC after SVR to DAA for chronic hepatitis C. Journal of Hepatology. 2018;68(Supplement 1):S535.	7
237	Sasaki R, Miyaaki H, Nakao K. Effectiveness of M2BPGi in the detection of liver graft fibrosis after living donor liver transplantation. Hepatology. 2018;68(Supplement 1):656A.	3
238	Sato K, Takakusagi S, Kosone T, Yamazaki Y, Horiguchi N, Kakizaki S, et al. SIGNIFICANT REDUCTION OF MAC-2 BINDING PROTEIN GLYCOSYLATION ISOMER (M2BPGI) PROTEIN LEVELS IN PATIENTS WHO ACHIEVED SUSTAINED VIROLOGICAL RESPONSE (SVR) BUT NOT THOSE COULD NOT BY THE COMBINATION THERAPY OF DACLATASVIR/ASUNAPREVIR. Gastroenterology. 2018;154(6 Supplement 1):S-729.	3
239	Seike T, Komura T, Shimizu Y, Omura H, Kumai T, Kagaya T, et al. Clinical significance of measuring serum M2BPGi level in patients with acute liver injury. Hepatology International. 2018;12(2):S189.	3
240	Setsu T, Tsuchiya A, Kimura N, Yokoo T, Sakamaki A, Kamimura H, et al. Screening for hepatocellular carcinoma using M2bpgi in primary care and specialist followup for collateral circulation and carcinoma risk evaluation using magnetic resonance elastography. Hepatology. 2018;68(Supplement 1):618A.	3

241	Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, et al. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. Journal of gastroenterology. 2018;53(7):883-9.	7
242	Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. Journal of gastroenterology. 2018;53(7):819-26.	2
243	Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, et al. Response to the letter by Dr. Naoya Yamada, and Dr. Koichi Mizuta regarding our manuscript: "Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis". Journal of Gastroenterology. 2018.	2
244	Sugiura A, Joshita S, Umemura T, Yamazaki T, Fujimori N, Kimura T, et al. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. Journal of viral hepatitis. 2018;25(12):1462-71.	7
245	Sugiura T, Dohi Y, Takase H, Mizoguchi T, Tanaka Y, Ohte N. Association of longitudinal changes in serum MAC-2 binding protein and low-density lipoprotein cholesterol levels: A prospective observational study. Circulation. 2018;138(Supplement 1).	7
246	Toyoda H, Kumada T, Tada T, Mizuno K. Imaging basis of AFP and WFA+M2BP as indicators of the risk of HCC after SVR. Journal of hepatology. 2018;68(3):606-7.	2
247	Tsuji K, Kurosaki M, Itakura J, Mori N, Takaki S, Hasebe C, et al. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. Journal of gastroenterology. 2018;53(10):1142-50.	7
248	Tsuzura H, Genda T, Amano N, Ayato M, Tomishima K, Sato S, et al. The significance of wisteria floribunda agglutinin-positive Mac-2-binding protein (M2BPGi) from the perspective of patients with hepatocellular carcinoma. Hepatology. 2018;68(Supplement 1):858A-9A.	3
249	Uchida Y, Naiki K, Kouyama JI, Sugawara K, Nakao M, Motoya D, et al. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy. PLoS ONE. 2018;13(10):e0205600.	7
250	Ugamura A, Chu PS, Nakamoto N, Taniki N, Ojiro K, Hibi T, et al. Liver Fibrosis Markers Improve Prediction of Outcome in Non-Acetaminophen-Associated Acute Liver Failure. Hepatology Communications. 2018;2(11):1331-43.	5
251	Yamasaki K, Mizokami M, Bekki S, Shimakura A, Kugiyama Y, Hashimoto S, et al. Combined use of WFA(+)-M2BP and AFP-l3 for the prediction of hepatocellular carcinoma development among patients with Hepatitis C virus; one size fits all from 100% rule-out in 5-years to 70% rule-in in 10-years. Hepatology. 2018;68(Supplement 1):917A.	7
252	Yasui Y, Kurosaki M, Nobuharu T, Komiyama Y, Takada H, Watakabe K, et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma in SVR achieved hepatitis C patients with interferon-free treatment. Journal of Hepatology. 2018;68(Supplement 1):S533.	7
253	Yeh ML, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL. Post-treatment wisteria floribunda agglutinin-positive Mac-2-binding protein combined with platelet predict hepatocellular carcinoma development in chronic hepatitis C patients. Hepatology International. 2018;12(2):S181-S2.	7

254	Zhong L, Liu Y, Wang K, He Z, Gong Z, Zhao Z, et al. Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma. BMC Cancer. 2018;18(1):911.	2
255	Zhu MY, Chen PZ, Li J, Yu DM, Huang D, Zhu XJ, et al. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-alpha treatment in HBeAg-positive chronic hepatitis B patients. Journal of Medical Virology. 2018;90(4):721-9.	7
256	Se Young J, Won Young T, Soo Young P, Young-oh K, Yu Rim L, Bina J, et al. The Diagnostic Efficacy of M2BPGi for Liver Fibrosis in HCC and NAFLD Patients. 춘·추계 학술대회 (KASL). 2018;2018(1):123-4.	3
257	조선영, 허미나. Mac-2 Binding Protein Glycosylation Isomer: Emerging Non-Invasive Serum Marker for Liver Fibrosis. Annals of Laboratory Medicine. 2018;38(4):289-90.	2
258	Xu H, Kong W, Liu L, Chi X, Wang X, Wu R, et al. Accuracy of M2BPGi, compared with Fibro Scan, in analysis of liver fibrosis in patients with hepatitis C. BMC Gastroenterology. 2017;17(1):62.	7
259	Fujiyama T, Ito T, Ueda K, Tachibana Y, Yasunaga K, Miki M, et al. Serum levels of Wisteria floribunda agglutinin-positive Mac-2 binding protein reflect the severity of chronic pancreatitis. Journal of digestive diseases. 2017;18(5):302-8.	7
260	Kajiyama H. Serum Mac-2-binding protein glycosylation isomer as a marker for non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus. Teikyo Medical Journal. 2017;40(6):273-80.	7
261	Mizuno M, Shima T, Oya H, Mitsumoto Y, Mizuno C, Isoda S, et al. Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers. Hepatology research : the official journal of the Japan Society of Hepatology. 2017;47(2):216-25.	6
262	Ahn SS, Park Y, Jung SM, Song JJ, Park YB, Lee SW. Serum wisteria floribunda agglutinin-positive mac-2-binding protein can reflect systemic lupus erythematosus activity. Arthritis and Rheumatology. 2017;69(Supplement 10).	5
263	Alkhouri N, Johnson C, Adams LA, Raheem SA, Lopez R, Kitajima S, et al. Serum Wisteria floribunda agglutinin-positive mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. Hepatology. 2017;66(Supplement 1):1134A.	3
264	Bekki Y, Yoshizumi T, Shimoda S, Itoh S, Harimoto N, Ikegami T, et al. Hepatic stellate cells secreting WFA+ -M2BP: Its role in biological interactions with Kupffer cells. Journal of gastroenterology and hepatology. 2017;32(7):1387-93.	7
265	Cheung KS, Seto WK, Wong DKH, Mak LY, Lai CL, Yuen MF. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. Oncotarget. 2017;8(29):47507-17.	7
266	Cheung KS, Wong DKH, Seto WK, Lai CL, Yuen MF. High level of Wisteria floribunda agglutinin-positive human Mac- 2 binding protein is associated with hepatocellular carcinoma development in chronic hepatitis B patients under antiviral treatment. Hepatology International. 2017;11(1 Supplement 1):S72.	7
267	Chuaypen N, Tanaka Y, Tangkijvanich P. Serum WFA+-M2BP level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma. Hepatology. 2017;66(Supplement 1):867A-8A.	3
268	Feng S, Wei B, Chen E, Li D, Wang T, Gou Y, et al. Predicting liver fibrosis staging using noninvasive biomarker M2BPGI in patients with hepatitis B infection. Clinical Chemistry. 2017;63(Supplement 1):S183.	3

269	Haga Y, Kanda T, Takahashi K, Nakamura M, Sasaki R, Wu S, et al. Serum Wisteria Floribunda agglutinin-positive Mac-2 binding protein and platelet counts in non-viral liver diseases. Hepatology International. 2017;11(1 Supplement 1):S118-S9.	3
270	Hidaka I, Sakaida I. A study of the effectiveness for improving hepatic fibrogenesis and suppressing hepatocarcinogenesis after SVR in DAA therapies. Journal of Gastroenterology and Hepatology. 2017;32(Supplement 3):182-3.	7
271	Hige S, Karino Y, Ozeki I, Tatsumi R, Yamaguchi M, Kimura M, et al. Evaluation of wisteria floribunda agglutinin-positive MAC-2 binding protein glycosylation isomer during the course of antiviral treatment. Hepatology. 2017;66(Supplement 1):555A-6A.	3
272	Hige S, Kuno A, Matsuda A, Korenaga M, Tatsumi R, Yamaguchi M, et al. Serum wisteria floribunda agglutinin-positive sialylated mucin 1 as a meaningful prognostic biomarker after hepatic resection for hcv-positive patients with hepatocellular carcinoma. Hepatology. 2017;66(Supplement 1):866A-7A.	7
273	Honda K, Seike M, Endo M, Iwao M, Tokoro M, Arakawa M, et al. Factors associated with continuous ALT elevation even after viral eradication using direct-acting antiviral therapy. Hepatology International. 2017;11(1 Supplement 1):S1002-S3.	7
274	Iio E, Shimada N, Matsuura K, Atsukawa M, Takaguchi K, Eguchi Y, et al. Investigating the association of tll1 variant with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free regimens. Hepatology. 2017;66(Supplement 1):521A.	7
275	Inoue T, Tanaka Y. [Clinical Significance of Novel Serum Biomarkers in the Management of Liver Diseases]. Rinsho byori The Japanese journal of clinical pathology. 2017;65(1):83-91.	4
276	Ishida K, Nakatani T, Motokawa Y, Tomooka F, Shibamoto A, Fujimoto Y, et al. Clinical features of patients developing HCC after achieving SVR with daa against chronic hepatitis c. United European Gastroenterology Journal. 2017;5(5 Supplement 1):A409.	7
277	Ito K, Murotani K, Nakade Y, Inoue T, Nakao H, Sumida Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: A meta-analysis. Journal of gastroenterology and hepatology. 2017;32(12):1922-30.	2
278	Joshita S, Umemura T, Usami Y, Sugiura A, Yamazaki T, Fujimori N, et al. Association of serum autotaxin level with disease stage in Japanese patients with primary biliary cholangitis. Journal of Gastroenterology and Hepatology. 2017;32(Supplement 3):179.	7
279	Jprn U. Clinical usefulness of serum Mac-2 binding protein glycosylation isomer in decompensated cirrhosis. https://trialsearchwhoint/Trial2aspx?TrialID=JPRN-UMIN000030234. 2017.	3
280	Kang JH, Tanaka K, Matsui T, Yamamoto Y, Utsunomiya R, Tsuji K, et al. Frequent deterioration in autoimmune hepatitis with acute presentation is not associated with acute AIH but acute exacerbation that could be differentiated from acute AIH by surrogate markers for liver fibrosis. Journal of Hepatology. 2017;66(1 Supplement 1):S543.	3
281	Kawaguchi T, Ide T, Amano K, Kuwahara R, Arinaga-Hino T, Miyjima I, et al. Changes in fibrotic markers in chronic hepatitis C patients treated with direct antiviral agents and the enhanced liver fibrosis score as a predictor of hepatocellular carcinoma. Hepatology. 2017;66(Supplement 1):554A-5A.	7
282	Kawanaka M, Nishino K, Tanikawa T, Oka T, Urata N, Nakamura J, et al. Effective biomarkers for advance fibrosis NASH and reflect biomarkers as changes of liver fibrosis with NASH. Hepatology. 2017;66(Supplement 1):1115A.	3

283	Kawanaka M, Nouso K, Yano S, Nakamura J, Nishino K, Suehiro M, et al. Case report of diet-related improvements of non-alcoholic steatohepatitis evaluated by four consecutive liver biopsies. Hepatology research : the official journal of the Japan Society of Hepatology. 2017;47(5):480-4.	7
284	Kim SU, Heo JY, Kim BK, Park JY, Kim DY, Han KH, et al. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. Liver International. 2017;37(6):879-87.	7
285	Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, et al. Analysis of biomarkers predictive of fibrosis progression in patients with fontan associated liver disease. Hepatology. 2017;66(Supplement 1):337A.	3
286	Lai LL, Chan WK, Sthaneshwar P, Mustapha NRN, Goh KL, Mahadeva S. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein as a serum biomarker for disease severity in nonalcoholic fatty liver disease. Journal of Hepatology. 2017;66(1 Supplement 1):S676.	3
287	Liang YY, Yu P. Clinical study of M2BPGi assessing liver fibrosis in patients with chronic hepatitis C. Hepatology International. 2017;11(1 Supplement 1):S911-S2.	3
288	Lin YJ, Chang CL, Chen LC, Hu HH, Liu J, Korenaga M, et al. Elevated serum wisteria floribunda agglutinin-positive mac-2- binding protein levels associated with risks of diabetes and endstage renal diseases among patients with hepatitis C virus infection. Journal of Hepatology. 2017;66(1 Supplement 1):S713.	7
289	Liu J, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, et al. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. Scientific reports. 2017;7(1):14352.	7
290	Morimoto N, Isoda N, Miura K, Watanabe S, Takaoka Y, Tsukui M, et al. Risk factors of development of hepatocellular carcinoma in HCV patients after direct-acting antiviral therapy. Journal of Gastroenterology and Hepatology. 2017;32(Supplement 3):156.	7
291	Morio K, Imamura M, Daijo K, Teraoka Y, Honda F, Nakamura Y, et al. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury. Journal of gastroenterology. 2017;52(12):1252-7.	5
292	Morisawa N, Koshima Y, Kuriyama S, Matsuyama M, Hayashi N, Satoh JI, et al. Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis. Nephrology. 2017;22(7):562-5.	7
293	Murakawa M, Asahina Y, Nakagawa M, Nitta S, Kawai-Kitahata F, Nagata H, et al. On-treatment higher levels of alpha-fetoprotein and M2BPGI are associated with development of hepatocellular carcinoma during nucleos(T)ide analog therapy in patients with HBV chronic infection. Hepatology. 2017;66(Supplement 1):507A.	7
294	Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. Journal of Hepatology. 2017;67(5):933-9.	7
295	Nakagawa M, Asahina Y, Nagata H, Kaneko S, Kawai-Kitahata F, Murakawa M, et al. Evaluation of an early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C patients treated with All-Oral DAAs-Propensity score-matched analysis of a prospective database-Propensity s. Hepatology. 2017;66(Supplement 1):38A-9A.	7
296	Nakao Y, Kugiyama Y, Bekki S, Uchida S, Hashimoto S, Saeki A, et al. The clinicopathological characteristics of newly diagnosed hepatocellular carcinoma shortly after ifn-free-daa therapy. Hepatology. 2017;66(Supplement 1):835A-6A.	3

297	Nishino K, Kawanaka M, Tanikawa T, Urata N, Oka T, Nakamura J, et al. Prediction of hepatocellular carcinoma following direct-acting antiviral treatment for chronic hepatitis C. Hepatology. 2017;66(Supplement 1):554A.	7
298	Okuda Y, Taura K, Yoshino K, Ikeno Y, Nishio T, Yamamoto G, et al. Usefulness of Mac-2 Binding Protein Glycosylation Isomer for Prediction of Posthepatectomy Liver Failure in Patients With Hepatocellular Carcinoma. Annals of surgery. 2017;265(6):1201-8.	7
299	Ozcaka O, Epstein JB, Guneri P. Inflammation in the assessment of salivary cytokines in oral squamous cell carcinoma diagnosis. Oral Oncology. 2017;71:96-8.	2
300	Suda T, Okawa O, Masaoka R, Gyotoku Y, Tokutomi N, Katayama Y, et al. Shear wave elastography in hepatitis C patients before and after antiviral therapy. World journal of hepatology. 2017;9(1):64-8.	7
301	Taura K, Yamamoto G, Nishio T, Okuda Y, Ikeno Y, Yoshino K, et al. Noninvasive evaluation of liver fibrosis as innovative tools for preoperative liver functional assessment for patients with hepatocellular carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences. 2017;24(Supplement 1):A77.	3
302	Tsuzura H, Genda T, Amano N, Murata A, Tomishima K, Sato S, et al. Post-treatment serum wisteria floribunda agglutinin-positive mac-2-binding protein levels predict the risk of hepatocellular carcinoma development after hepatitis C virus eradication. Hepatology. 2017;66(Supplement 1):628A-9A.	7
303	Ugamura A, Chu PS, Nakamoto N, Taniki N, Takeda K, Ebinuma H, et al. Modification of the meld score with serological fibrosis markers reflecting extracellular matrix remodeling improves prediction of outcomes in non-acetaminophen-associated acute liver failure. Hepatology. 2017;66(Supplement 1):682A-3A.	5
304	Waragai Y, Suzuki R, Takagi T, Sugimoto M, Asama H, Watanabe K, et al. Clinical significance of serum wisteria floribunda agglutinin-positive mac-2 binding protein in pancreatic ductal adenocarcinoma. Gastroenterology. 2017;152(5 Supplement 1):S276.	3
305	Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, et al. Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2. Journal of medical virology. 2017;89(9):1567-73.	7
306	Xie H, Zhang Z, Chen L, Zhang P, Cui Y, Liu H, et al. Elevated plasma levels of Mac-2 binding protein predict poor cardiovascular outcomes in patients with acute coronary syndrome. Coronary artery disease. 2017;28(8):683-9.	5
307	Yang YY, Xu H, Pan Y, Niu J. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of M2BPGi and aspartate aminotransferaseplatelet ratio index. Hepatology International. 2017;11(1 Supplement 1):S1042.	7
308	Zhu M, Huang W, Chen Y, Han Y, Gong Q, Chen P, et al. Baseline serumWFA+-M2BP level is a strong predictor of response to pegylated interferon-alpha in HBeAg-positive chronic hepatitis B patients. Journal of Hepatology. 2017;66(1 Supplement 1):S481.	7
309	Zolzaya D, Ganchimeg D, Anarmaa M, Lkhaasuren N, Tegshjargal B, Sarantuya G, et al. HLA-DP Polymorphisms on HBV, HDV Superinfection in Mongolian Individuals. 춘·추계 학술대회 (KASL). 2017;2017(1):92-.	3
310	김석현, 임지애, 김소영, 이경민, 최원정. M2BPGi 간 섬유화 검사 [화학발광효소면역측정법]. 신의료기술평가 보고서. 2017;1(14):1-99.	3
311	임지애, 김소영, 최원정, 김석현. M2BPGi 간 섬유화 검사 : 체계적 문헌고찰. 근거와 가치. 2017;3(2):131-7.	2
312	Haga Y, Kanda T, Sasaki R, Nakamura M, Takahashi K, Wu S, et al. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Could Not Always Predict Early Cirrhosis in Non-Viral Liver Diseases. Diseases (Basel, Switzerland). 2016;4(4).	7

313	Hasegawa K, Takata R, Nishikawa H, Enomoto H, Ishii A, Iwata Y, et al. Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis. International journal of molecular sciences. 2016;17(9).	7
314	Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, et al. Clinical implication of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level on hepatitis B e-antigen loss or seroconversion in hepatitis B e-antigen positive patients. Hepatology research : the official journal of the Japan Society of Hepatology. 2016;46(11):1065-73.	7
315	Bapat R, Kheur S, Kheur M, Sethi T, Gupta AA. Role of interleukin 8 in oral squamous cell carcinoma: A systematic review. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2016;7(2):436-42.	2
316	Bekki Y, Shirabe K, Shimoda S, Itoh S, Ikegami T, Uchiyama H, et al. WFA(+)-M2BP interacts with Kupffer Cells which activates Hepatic stellate cells. Hepatology International. 2016;10(1 SUPPL. 1):S77.	7
317	Chang CL, Chen LC, Hu HH, Lin YJ, Liu J, Jen CL, et al. Serum levels of wisteria floribunda agglutinin-positive Mac-2 binding protein as a time-dependent predictor of hepatocellular carcinoma in chronic hepatitis C patients. Hepatology. 2016;64(1 Supplement 1):371A-2A.	7
318	Chen LC, Liu J, Hu HH, Yang HI, Korenaga M, Jen CL, et al. Serum levels of Mac-2 binding protein and the associated risk for HCC among CHC patients. Hepatology International. 2016;10(1 SUPPL. 1):S13.	7
319	Endo M, Honda K, Iwao M, Tokoro M, Arakawa M, Oribe J, et al. Noninvasive assessment of liver fibrosis using RTE and a novel serum marker: WFA+-M2BP. Hepatology International. 2016;10(1 SUPPL. 1):S353.	3
320	Fujiyama T, Ueda K, Tachibana Y, Miki M, Yasunaga K, Takaoka T, et al. Serum level of wisteria floribunda agglutinin-positive MAC-2-binding protein reflects the severity of chronic pancreatitis. Pancreas. 2016;45(10):1505.	3
321	Genda T, Ichida T, Amano N, Sato S, Murata A, Tsuzura H, et al. Prediction of hepatocellular carcinoma development after hepatitis C virus eradication using serum wisteria floribunda agglutinin-positive Mac-2-binding protein. International Journal of Molecular Sciences. 2016;17(12):2143.	7
322	Hamano M, Naito M, Tokuda Y, Tatsumi N, Ito T. Glyco-isomer of serum Mac-2-binding protein (M2BPGi) were dramatically decreased due to anti-viral therapy in chronic hepatitis C (CHC) patients. Hepatology. 2016;64(1 Supplement 1):966A-7A.	7
323	Hayashi T, Tamaki N, Kurosaki M, Izumi N. The Usefullness of WFA-M2BP for predicting gastroesophageal varices and liver related events in HCV-related cirrhosis. Hepatology. 2016;64(1 Supplement 1):842A.	3
324	Heo JY, Ahn SS, Kim SU, Kim BK, Park JY, Kim DY, et al. Risk assessment of hepatocellular carcinoma using wisteria floribunda agglutinin-positive human Mac-2 binding protein in chronic hepatitis B patients. Journal of Hepatology. 2016;64(2 SUPPL. 1):S724.	3
325	Hige S, Karino Y, Ozeki I, Yamaguchi M, Kimura M, Arakawa T, et al. The real world experience of daclatasvir and asunaprevir combination therapy for more elderly patients than the clinical trial subjects with genotype 1b chronic hepatitis C. Journal of Hepatology. 2016;64(2 SUPPL. 1):S819.	7
326	Hu HH, Chang CL, Liu J, Jen CL, Luo WS, Lin YL, et al. WFA+-M2BP as a predictor of hepatocellular carcinoma in individuals who were seronegative for both HBV surface antigen and anti-HCV antibody. Hepatology. 2016;64(1 Supplement 1):217A.	7

327	Huang JF, Huang CI, Yu ML, Dai CY, Chuang WL. Serum Wisteria floribunda agglutininpositive mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients. Journal of Gastroenterology and Hepatology (Australia). 2016;31(Supplement 3):382.	3
328	Ichikawa Y, Joshita S, Umemura T, Matsumoto A, Tanaka E. Serum autotaxin can predict liver fibrosis in patients with chronic hepatitis b virus infection. United European Gastroenterology Journal. 2016;4(5 Supplement 1):A542.	6
329	Inaba T, Ikemoto T. [Industry-Academia Collaboration in the Clinical Laboratory Field: Chairmen's Introductory Remarks]. Rinsho byori The Japanese journal of clinical pathology. 2016;64(1):99-100.	4
330	Inoue T, Tsuzuki Y, Iio E, Ohne K, Shinkai N, Ohike T, et al. Clinical evaluation of liver fibrosis and hepatocarcinogenesis using a novel glycobiomarker Wisteria floribunda agglutinin+-Mac-2 binding protein (M2BPGi). Hepatology. 2016;64(1 Supplement 1):398A.	3
331	Itokawa N, Atsukawa M, Okubo T, Arai T, Nakagawa A, Kondo C, et al. Serum M2BPGi and HVPG are useful factors predicting the effect of tolvaptan on hepatic edema. Hepatology International. 2016;10(1 SUPPL. 1):S385.	7
332	Kawaguchi K, Honda M, Terashima T, Shimakami T, Arai K, Sakai Y, et al. Prediction of hepatitis B virus-related liver cancer incidence and recurrence after anticancer therapy by hybrid evaluation of serum WFA(+)-M2BP and hepatitis B core-related antigen. Hepatology. 2016;64(1 Supplement 1):893A.	7
333	Kawanaka M, Nishino K, Nakamura J, Suehiro M, Kawamoto H, Nakade Y, et al. Significance of measuring serum wisteria floribunda agglutinin-positive mac-2 binding protein for observing hepatic fibrosis in patients with nonalcoholic fatty liver disease: Analysis of repeated biopsied cases. Acta Hepatologica Japonica. 2016;56(12):678-9.	4
334	Kawanaka M, Nishino K, Nakamura J, Tanikawa T, Oka T, Urata N, et al. Using WFA +M2BP to determine drug free status and clearance of HBs antigen in sequential therapy. Acta Hepatologica Japonica. 2016;57(8):412-5.	4
335	Kawanaka M, Nishino K, Nakamura J, Tanikawa T, Urata N, Oka T, et al. Elevated WFAM2BP, ALT flare and HBs decline)1.0Log/ ml during Peg IFN were predict drug free and HBs antigen clearance in sequential therapy with Peg-IFN alfa-2a on long-term nucleoside analog treated patients. Hepatology. 2016;64(1 Supplement 1):941A.	7
336	Korenaga M, Korenaga K, Imamura M, Aoki Y, Sugiyama M, Kanto T, et al. Utility of MAC-2 binding protein glycosylation isomer (M2BPGi) for advanced fibrosis and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Journal of Hepatology. 2016;64(2 SUPPL. 1):S732-S3.	3
337	Korenaga M, Korenaga K, Ueyama M, Kumagai E, Aoki Y, Sugiyama M, et al. Ledipasvir/sofosbuvir reduces risk factors associated with HCC in patients with chronic hepatitis C. Hepatology International. 2016;10(1 SUPPL. 1):S18.	7
338	Kudo M. Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response. Liver Cancer. 2016;5(3):155-61.	2
339	Kugiyama Y, Yamasaki K, Nagata K, Bekki S, Hashimoto S, Uchida S, et al. Serum M2BPGi and sodium level are associated with increased risk of mortality in patients with LC. Hepatology International. 2016;10(1 SUPPL. 1):S491-S2.	7
340	Liu J, Hu HH, Yang HI, Korenaga M, Lee MH, Jen CL, et al. Serum levels of wisteria floribunda agglutinin-positive Mac-2 binding protein as short-term predictors of hepatocellular carcinoma in chronic hepatitis B. Journal of Hepatology. 2016;64(2 SUPPL. 1):S363-S4.	7
341	Mano Y, Kumagai E, Shoji H, Yoshio S, Sugiyama M, Korenaga M, et al. Serum YKL-40 as a marker of liver fibrosis and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Hepatology. 2016;64(1 Supplement 1):799A.	7

342	Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M, et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatology research : the official journal of the Japan Society of Hepatology. 2016;46(8):758-64.	7
343	Murakoshi D, Sonoda A, Shimada T, Sahashi T, Touyama K. Study on reference ranges and potent risk factors of M2BPGi (liver fibrosis markers) in apparent healthy subjects. Japanese Journal of Clinical Chemistry. 2016;45(4):348-55.	5
344	Nagata H, Nakagawa M, Nishimura-Sakurai Y, Asano Y, Tsunoda T, Miyoshi M, et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatology International. 2016;10(6):956-64.	7
345	Nagata H, Sakurai Y, Nakagawa M, Kakinuma S, Azuma S, Murakawa M, et al. Serial changes in M2BPGi levels as predictors of fibrosis and HCC in chronic hepatitis C. Hepatology International. 2016;10(1 SUPPL. 1):S460.	3
346	Nakamura M, Kanda T, Haga Y, Nakamoto S, Wu S, Yokosuka O. Serum microRNA-122 as well as WFA(+)-M2BP is a good predictor of liver fibrosis in chronic hepatitis B infection. Hepatology. 2016;64(1 Supplement 1):900A-1A.	3
347	Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study. Journal of viral hepatitis. 2016;23(12):977-84.	7
348	Nishino K, Kawanaka M, Nakamura J, Tanikawa T, Urata N, Oka T, et al. The level of WFA+M2BP levels and alpha-fetoprotein levels are predicted hepatocellular carcinoma after sustained virologic responce with chronic hepatitis C patients. Hepatology. 2016;64(1 Supplement 1):724A.	7
349	Numao H, Shimaya K, Kakuta A, Hasui K, Shibutani K. Utility of real-time shear wave elastography in the assessment of liver fibrosis in patients with chronic liver disease. Hepatology. 2016;64(1 Supplement 1):213A.	3
350	Numao H, Shimaya K, Kakuta A, Shibutani K, Kurotaki H, Igarashi S, et al. Utility of real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis c. United European Gastroenterology Journal. 2016;4(5 Supplement 1):A109.	3
351	Okuda Y, Taura K, Ikeno Y, Nishio T, Yamamoto G, Tanabe K, et al. Mac 2 binding protein Gi for the prediction of posthepatectomy liver failure in hepatocellular carcinoma patients. HPB. 2016;18(SUPPL. 1):e217.	7
352	Sato S, Genda T, Ichida T, Amano N, Sato S, Murata A, et al. Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein. International journal of molecular sciences. 2016;17(12).	7
353	Shigefuku R, Takahashi H, Nakano H, Watanabe T, Matsunaga K, Matsumoto N, et al. Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C Virus. International journal of molecular sciences. 2016;17(9).	6
354	Shinkai N, Iio E, Matsuura K, Fujiwara K, Matsunami K, Nojiri S, et al. WFA+-Mac-2 binding protein is a predicting biomarker for HCC in hepatitis B patients. Hepatology International. 2016;10(1 SUPPL. 1):S276.	3

355	Suetsugu A, Ishida H, Hasegawa K, Hanai T, Shiraki M, Seishima M, et al. Change in serum levels of M2BPGi in patients with HCV during the treatment of Peg-IFN and RBV. Hepatology International. 2016;10(1 SUPPL. 1):S124.	7
356	Sung PS, Jekarl DW, Jang JW, Bae SH, Choi JY, Kim Y, et al. Serum wisteria floribunda agglutinin-positive MAC-2-binding protein level as a predictor of hepatic fibrosis in chronic HBV infection. Hepatology. 2016;64(1 Supplement 1):214A.	3
357	Totani H, Kusumoto S, Tanaka Y, Suzuki N, Hagiwara S, Kinoshita S, et al. The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy. International journal of hematology. 2016;104(3):384-91.	7
358	Toyoda H, Kumada T, Tada T. Response to 'WFA(+)-M2BP: a novel biomarker with diagnostic and therapeutic implications in liver diseases'. Liver international : official journal of the International Association for the Study of the Liver. 2016;36(4):613.	2
359	Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Korenaga M, et al. Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver international : official journal of the International Association for the Study of the Liver. 2016;36(2):293-301.	7
360	Tsuruno C, Kagawa T, Takahama Y. Clinical significance of novel diagnostic assay "HISCL M2BPGi Assay Kit" which detects the glycosylation changes related to liver fibrosis stage. Japanese Journal of Clinical Chemistry. 2016;45(3):262-8.	4
361	Uchida S, Yamasaki K, Hayashi K, Kugiyama Y, Bekki S, Hashimoto S, et al. Association between Liver stiffness measurement and serum Wisteria floribunda agglutinin-positive Mac-2 binding protein among Japanese patients with hepatitis B, C and NAFLD/NASH. Hepatology. 2016;64(1 Supplement 1):392A.	3
362	Ura K, Furusyo N, Ogawa E, Nomura H, Yamashita N, Murata M, et al. Rapid decrease of the non-invasive serum liver fibrosis marker WFA+-M2BP by IFN-free therapy. Hepatology International. 2016;10(1 SUPPL. 1):S151.	3
363	Ura K, Furusyo N, Takayama K, Hiramine S, Kaseida-Mitsumoto F, Kato Y, et al. Age and female are the risk factors for HCC even in chronic hepatitis C patients with SVR. Hepatology International. 2016;10(1 SUPPL. 1):S159-S60.	7
364	Wang Q, Zhang X, Han Y, Wang X, Gao G. M2BP inhibits HIV-1 virion production in a vimentin filaments-dependent manner. Scientific reports. 2016;6:32736.	2
365	Waragai Y, Suzuki R, Takagi T, Sugimoto M, Asama H, Watanabe K, et al. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. Pancreatology. 2016;16(6):1044-50.	7
366	Watanabe H, Ito M, Nakazawa Y, Ito N, Ishihama K. Glyco-isomer of serum MAC-2-binding protein is associated with the risk of developing hepatocellular carcinoma after achieving sustained viral response in japanese chronic hepatitis C patients. Gastroenterology. 2016;150(4 SUPPL. 1):S923.	7
367	Wong D, Seto WK, Fung J, Chong CK, Lai CL, Yuen MF. Serum wisteria floribunda agglutinin-positive Mac-2 binding protein levels correlated with necroinflammation and fibrosis activities in chronic hepatitis B patients. Hepatology. 2016;64(1 Supplement 1):330A.	3
368	Zhou D, Wang Y, Zhang W, Chen L, Luan J. WFA(+)-M2BP: a novel biomarker with diagnostic and therapeutic implications in liver diseases. Liver international : official journal of the International Association for the Study of the Liver. 2016;36(4):612.	2

369	Dong Wook J, Pil Soo S, Bo Hyun J, Kwang Il S, Jeong Won J, Si Hyun B, et al. Serum Wisteria Floribunda Agglutinin-positive Mac-2-binding Protein Level as a Predictor of Hepatic Fibrosis in Chronic HBV Infection. 춘·추계 학술대회 (KASL). 2016;2016(1):57-8.	3
370	Ja Yoon H, Beom Kyung K, Jun Yong P, Do Young K, Sang Hoon A, Kwang-hyub H, et al. Risk Assessment of Developing Hepatocellular Carcinoma Using Wisteria Floribunda Agglutinin-positive Human Mac-2 Binding Protein in Chronic Hepatitis B Patients. 춘·추계 학술대회 (KASL). 2016;2016(1):71-.	3
371	Hanai T, Shiraki M, Ohnishi S, Miyazaki T, Ideta T, Kochi T, et al. Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatology research : the official journal of the Japan Society of Hepatology. 2015;45(11):1083-90.	7
372	Bekki S, Yamasaki K, Sonoda Y, Kugiyama Y, Hashimoto S, Saeki A, et al. Elevated serum wisteria floribunda agglutinin-positive human Mac-2 binding protein predict all-cause mortality in hepatitis C patients with hepatocellular carcinoma. Hepatology. 2015;62(SUPPL. 1):416A.	7
373	Hamano M, Naito M, Ito T. Glyco-isomer of serum Mac-2-binding protein is the most useful biomarker for liver fibrosis in patients with chronic hepatitis C. Hepatology. 2015;62(SUPPL. 1):606A.	3
374	Hamano M, Naito M, Kawasaki Y, Tokuda T, Matsushita M, Sato Y, et al. Usefulness of liver fibrosis assessment in patients with chronic hepatitis C (CHC) using glyco-isomer of serum MAC-2-binding protein. United European Gastroenterology Journal. 2015;3(5 SUPPL. 1):A342.	3
375	Hige S, Karino Y, Ozeki I, Yamaguchi M, Kimura M, Arakawa T, et al. Early reduction of serum fibrosis marker and tumor marker in patients treated with daclatasvir and asunaprevir. Journal of Viral Hepatitis. 2015;22(SUPPL. 2):92-3.	7
376	Hige S, Ozeki I, Yamaguchi M, Kimura M, Arakawa T, Nakajima T, et al. A unique glycoprotein; Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) is a disease-specific serum marker for liver fibrosis. Journal of Viral Hepatitis. 2015;22(SUPPL. 2):102-3.	3
377	Iio E, Ocho M, Togayachi A, Kuno A, Shinkai N, Ikehara Y, et al. A novel glycobiomarker wisteria floribunda agglutinin + MAC 2 binding protein for predicting carcinogenesis and survival of liver cirrhosis patients. Hepatology International. 2015;9(1 SUPPL. 1):S333-S4.	7
378	Ikeda H, Shigefuku R, Hattori N, Matsunaga K, Watanabe T, Matsumoto N, et al. Serum wisteria floribunda agglutinin-positive human mac-2 binding protein (WFA+-M2BP) levels of severe fibrosis varies according to the etiology of liver disease. Hepatology. 2015;62(SUPPL. 1):915A.	3
379	Ishida H, Suetsugu A, Nakamura M, Tauchi R, Nakayama J, Katano Y, et al. [Change in Serum Levels of New Hepatic Fibrosis Marker "Mac-2 Binding Protein Glycosylation isomer (M2BPGi)" in Patients with Chronic Hepatitis C during the Treatment of Pegylated Interferon and Ribavirin]. Rinsho byori The Japanese journal of clinical pathology. 2015;63(8):901-6.	4
380	Ishii A, Enomoto H, Nishikawa H, Kishino K, Shimono Y, Nakano C, et al. The relationship between the presence of esophageal varices and the Wisteria floribunda agglutinin-positive Mac-2-binding protein level in patients with Child-Pugh A liver cirrhosis. Hepatology. 2015;62(SUPPL. 1):593A.	3
381	Kawanaka M, Hyogo H, Koda M, Shima T, Hara Y, Tobita H, et al. The glycosylation marker M2BPGi predicts the development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology. 2015;62(SUPPL. 1):1279A-80A.	7
382	Kawanaka M, Nishino K, Tanogawa T, Oka T, Urata N, Nakamura J, et al. Elevated serum levels of M2BPGi predict the burned out nash and hepatocellular carcinoma with non-alcoholic steatohepatitis. Liver Cancer. 2015;4(SUPPL. 1):221.	3

383	Korenaga M, Korenaga K, Mizokami M. [Human Mac-2 binding protein glycosylation isomer (M2BPGi), a glycomarker, as a predictor of liver fibrosis for the patients with HCV]. Nihon rinsho Japanese journal of clinical medicine. 2015;73 Suppl 9:230-7.	4
384	Kugiyama Y, Yamasaki K, Sonoda Y, Bekki S, Hashimoto S, Uchida S, et al. Serum wisteria floribunda agglutinin-positive human Mac-2 binding protein is associated with an increased risk of mortality in patients with liver cirrhosis. Hepatology. 2015;62(SUPPL. 1):599A.	7
385	Kumagai E, Korenaga M, Korenaga K, Ueyama M, Imamura M, Sugiyama M, et al. Usefulness of mac-2 binding protein glycosylation isomer (M2BPGi) for advanced fibrosis and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Hepatology. 2015;62(SUPPL. 1):1277A.	3
386	Matsumoto A. [Usefulness of monitoring of M2BPGi during natural course and therapy]. Nihon rinsho Japanese journal of clinical medicine. 2015;73 Suppl 9:476-80.	4
387	Nakajima T, Ozeki I, Hige S, Karino Y, Toyota J. WFA+-M2BP is a predictive factor for fibrosis progression in NAFLD. Journal of Hepatology. 2015;62(SUPPL. 2):S721.	3
388	Narimatsu H. Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics. Expert review of proteomics. 2015;12(6):683-93.	2
389	Nishio T, Taura K, Tanabe K, Yamamoto G, Okuda Y, Ikeno Y, et al. Prediction of posthepatectomy liver failure based on preoperative liver fibrosis assessment: Comparison of Mac-2 binding protein glycosylation isomer and liver stiffness measurement. Hepatology. 2015;62(SUPPL. 1):810A.	3
390	Oda K, Uto H, Mawatari S, Ibusuki R, Ijuin S, Onishi H, et al. Serum levels of wisteria floribunda agglutinin-positive human Mac-2 binding protein are useful for evaluating early liver fibrosis in hepatitis C patients. Hepatology. 2015;62(SUPPL. 1):1104A-5A.	3
391	Ozeki I. Clinical significance of blood asunaprevir concentrations levels during combined daclatasvir and asunaprevir therapy. Hepatology. 2015;62(SUPPL. 1):805A.	7
392	Sasaki R, Yamasaki K, Abiru S, Komori A, Nagaoka S, Saeki A, et al. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. PloS one. 2015;10(6):e0129053.	7
393	Sato S, Tsuzura H, Genda T, Nagahara A. Wisteria floribunda agglutinin-positive Mac-2-binding protein predicts hepatocellular carcinoma development in chronic hepatitis C patients who achieved sustained virological response to interferon-based anti-viral therapy. Hepatology. 2015;62(SUPPL. 1):1112A.	7
394	Shibata H, Kakuda H, Morikawa T, Funakoshi K. [Measurement of Liver Fibrosis Marker Targeting Sugar Chain Marker]. Rinsho byori The Japanese journal of clinical pathology. 2015;63(1):72-7.	4
395	Tamaki N, Kurosaki M, Izumi N. [Noninvasive Estimation of Liver Fibrosis and Hepatocellular Carcinoma Development Using WFA(+)-M2BP in Chronic Hepatitis C Patients]. Rinsho byori The Japanese journal of clinical pathology. 2015;63(9):1039-43.	4
396	Tamaki N, Kurosaki M, Kuno A, Korenaga M, Togayachi A, Gotoh M, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatology research : the official journal of the Japan Society of Hepatology. 2015;45(10):E82-8.	7
397	Tawara S, Tatsumi T, Iio S, Kobayashi I, Suemura S, Takigawa A, et al. Evaluation of both fucosylated haptoglobin and Mac-2 binding protein as new biomarkers to estimate liver fibrosis in chronic hepatitis C patients. Hepatology. 2015;62(SUPPL. 1):1090A-1A.	3

398	Yamasaki K, Bekki S, Kugiyama Y, Uchida S, Saeki A, Hashimoto S, et al. Elevated serum levels of WFA(+)-M2BP predict the development of hepatocellular carcinoma in hepatitis B patients with HBeAg. Hepatology. 2015;62(SUPPL. 1):990A-1A.	7
399	Yoshida S, Shimada M, Tobari M, Nishino T. Transient elastography and serum MAC-2 binding protein (M2BPGI) may reflect amyloid deposition in al hepatic amyloidosis: A rare and curious case. American Journal of Gastroenterology. 2015;110(Supplement 1):S360-S1.	7
400	Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, et al. Wisteria floribunda agglutinin-positive MAC-2 binding protein as a predictor of liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatology. 2014;60(SUPPL. 1):418A-9A.	3
401	Hige S, Ozeki I, Kimura M, Arakawa T, Nakajima T, Kuwata Y, et al. Evaluation of liver fibrosis and prediction of hepatic carcinogenesis for patients with chronic hepatitis B by a unique glycoprotein: Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP). Hepatology. 2014;60(SUPPL. 1):981A-2A.	3
402	Kawanaka M, Nishino K, Nakamura J, Oka T, Urata N, Goto D, et al. Wfa-M2bp levels are usefull indicators of progression and inprovement for monitoring liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 2014;60(SUPPL. 1):630A-1A.	3
403	Sasaki R, Yamasaki K, Mine A, Kugiyama Y, Bekki S, Hashimoto S, et al. The relationship of Wisteria floribunda agglutinin-positive human Mac-2 binding protein and hepatocellular carcinoma developed after sustained virological response against hepatitis C virus. Hepatology. 2014;60(SUPPL. 1):914A.	3
404	Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology (Baltimore, Md). 2014;60(5):1563-70.	7
405	Yamasaki K, Kuno A, Korenaga M, Togayachi A, Ocho M, Tateyama M, et al. WFA(+)-M2BP is a new and unique glycobiomarker to predict the development of HCC in patients with chronic HCV infection. Hepatology. 2013;58(4 SUPPL. 1):594A-5A.	7
406	Hellstern S, Sasaki T, Fauser C, Lustig A, Timpl R, Engel J. Functional studies on recombinant domains of Mac-2-binding protein. The Journal of biological chemistry. 2002;277(18):15690-6.	5